Clinical Trial Aims to Unravel Genetic Markers of MRD in Multiple Myeloma Patients
The Multiple Myeloma Research Foundation (MMRF) and the Memorial Sloan Kettering Cancer Center are collaborating to launch a new clinical trial studying minimal…
News
Excess Body Fat Increases Risk for 8 More Cancer Types, Special Report Says
The association between excess body fat and increased risk of various cancers is an undisputed fact. Now, the findings of a working group from the International…
Minimal Residual Disease in Myeloma Suggested as Clinical Trial Endpoint, but Experts Disagree
Minimal residual disease, a measurement that shows a low level of disease detected, should be used as an endpoint in myeloma clinical trials, a study…
Janssen Seeks to Expand Darzalex Use for Multiple Myeloma Patients
Janssen Biotech has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand Darzalex (daratumumab) to include…
In Heavily Treated Myeloma Patients, Selinexor-Dexamethasone Combo Shows Positive Results
Patients with heavily treated multiple myeloma have promising response rates when treated with a combination of selinexor (KPT-330) and low-dose dexamethasone, according to the results…
Survival of Younger Myeloma Patients Influenced by Marriage and Insurance, not Ethnicity, Study Finds
With advances in treatment for multiple myeloma, some studies have reported improved survival rates, especially among young white patients and, to a lesser extent, in patients…
Myeloma Patients on Darzalex Combination Treatment Fared Better in Clinical Trial
Adding Darzalex (daratumumab) to the treatment of multiple myeloma with Velcade (bortezomib) and dexamethasone significantly improved progression-free survival in a clinical trial of patients who…
German Agency Questions Benefit of Empliciti Reported in Multiple Myeloma Study
Empliciti (elotuzumab), a monoclonal antibody, is approved in both the U.S. and Europe as a treatment, in combination with Revlimid (lenalidomide) and Decatron (dexamethasone), for multiple myeloma patients who…
Biotech Companies Partner with Memorial Sloan Kettering to Develop Multiple Myeloma Immunotherapy Program
Juno Therapeutics and privately held biotech Eureka Therapeutics have entered into an immunotherapy development partnership with Memorial Sloan Kettering Cancer Center…
Relapsed, Refractory Multiple Myeloma Progression Free Survival Prolonged with Drug Combo
Elotuzumab in combination with bortezomib and dexamethasone prolongs the progression free survival of patients with relapsed or refractory multiple myeloma (RRMM), according to…
